| 1999-04 |
Founded DNH Chip Research Institute in Hodogaya-ku, Yokohama City, Kanagawa Prefecture (capital: 22 million yen), and started DNA chip research. Began joint research with Hitachi Software Engineering, Ltd. (now Hitachi Ltd.). |
| 1999-04-01 |
Founded DNH Chip Research Institute Inc. in 1999. Developed DNA chips that comprehensively detect gene expression, aiming to contribute to future diagnostics and drug discovery. Launched Japan's first yeast chip and various general-purpose chips, followed by the development of analysis software and devices, establishing a business based on product sales. |
| 1999-08 |
Started selling the first domestically produced general-purpose DNA chip, "Yeast chip ver.1.0." |
| 2001 |
Relocated headquarters and consolidated research systems. |
| 2001-12 |
Relocated and consolidated headquarters to Tsurumi-ku, Yokohama City, in the "Yokohama Science Frontier" district. |
| 2002 |
Changed the company name to 'DNA Chip Research Institute Inc.' |
| 2002-09 |
Started selling "AceGene Human Oligo Chip 30K." |
| 2002-11 |
Changed the company name to "DNA Chip Research Institute, Inc." |
| 2003-06 |
Split one common stock into two (additional stocks due to split: 6,300 common stocks). Started selling "AceGene Mouse Oligo Chip 30K." |
| 2004-03 |
Listed on the Tokyo Stock Exchange Mothers Market. |
| 2004-06 |
Started selling "AceGene 30K on One Chip Version." |
| 2005-05 |
Split one common stock into two (additional stocks due to split: 13,600 common stocks). |
| 2005-11 |
Developed a new amino acid reagent and signed a licensing agreement with Sigma-Aldrich Japan Co., Ltd. |
| 2006-04 |
Started selling "AceGene Premium Human." |
| 2006-06 |
Issued the first unsecured convertible bond with stock acquisition rights. |
| 2006-11 |
Formed a strategic alliance with U.S. Agilent Technologies Inc. in the DNA microarray business. |
| 2006-12 |
The full conversion of the 1st unsecured convertible bond with stock acquisition rights into shares has been completed. |
| 2007-05 |
Developed "ConPath Chip" and "ConPath Navigator" and started a new contract analysis business. |
| 2007-08 |
Started selling genetic analysis teaching materials "Hybrid Teacher" for school education. |
| 2007-11 |
"Probe Bank" received the Encouragement Award at the 24th Kanagawa Industrial Technology Development Award. |
| 2008-03 |
Transferred genome analysis business from Hubbit Genomics Inc. Started clinical trials for efficacy diagnosis of rheumatoid arthritis antibody drugs using RNA check. Started a breast cancer prognosis prediction testing service using "MammaPrint". |
| 2009-04 |
Received Privacy Mark certification. |
| 2010-07 |
Takeda Rika Industry Co., Ltd. formed a strategic partnership with Wafergen Biosystems, Inc. in the United States. Started exclusive sales and contract services for next-generation ultra-high-speed ultra-sensitive real-time PCR device ("SmartChip") in Japan. |
| 2011-01 |
Formed a business alliance with Riken Genesis Co., Ltd. for genetic analysis services. |
| 2011-03 |
Product announcement and sales start of clinical research gene expression database "iCIS-crdb". |
| 2011-04 |
Product announcement and sales start of rheumatoid arthritis interview system "iRIS" for clinical settings. |
| 2011-12 |
Product announcement and sales start of DNA extraction kit for hard tissues (teeth and bones) "TBONE EX KIT". |
| 2013-10 |
Split ordinary shares into 100 shares (additional shares due to split: 3,355,803 ordinary shares) and adopted a unit share system (unit share: 100 shares). |
| 2013-10 |
Formed a strategic partnership with U.S. Agilent Technologies Inc. in the next-generation sequencing analysis business. |
| 2014-08 |
Changed stock listing market to the Tokyo Stock Exchange Second Section. |
| 2014-11 |
Entered into a capital and business alliance with Enplas Corporation (increased capital to 1.402 billion yen). |
| 2015-11 |
Relocated research facilities and offices to Minato Ward, Tokyo. |
| 2017-06 |
Transitioned from a company with a board of auditors to a company with an audit and supervisory committee. |
| 2020-05 |
Dissolved the capital and business alliance agreement with Enplas Corporation. |
| 2021-11 |
Formed a business alliance with GeneMetrics LLC on lung cancer compact panel business. |
| 2022-10 |
Established a medical laboratory in Kawasaki City, Kanagawa Prefecture. |
| 2023-01 |
Entered into a capital and business alliance agreement with Mitsui Chemicals, Inc. |
| 2024-10 |
Relocated the office to Kawasaki City, Kanagawa Prefecture. |
| 2025-04 |
The tender offer by Mitsui Chemicals, Inc. for our shares was successful. |
| 2025-06 |
Implemented a share consolidation through a tender offer. Transitioned from a company with an Audit and Supervisory Committee to a company with an Audit Committee. Delisted from the Tokyo Stock Exchange Standard Market. |
